News and analysis on disease research and diagnostics.
The Phase I trial, which will focus on studying BRAF-mutated solid tumors, has enrolled its first patient in Australia and will soon expand to sites in the US.
The FDA had previously approved neratinib as an extended adjuvant therapy for patients with early-stage HER2-overexpressed or amplified breast cancer, following adjuvant treatment with trastuzumab.
Pembrolizumab provided long-term overall survival benefit in second-line treatment and can be effectively used for retreatment after disease progression.
The Phase I trial is hosted at two locations in Europe and will enroll up to 60 patients whose tumors overexpress the PI3K delta protein.
The partnership aims to analyze the differences in the tumor microenvironments of cancer patients and use that to classify tumors and determine treatment prognosis.
